Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Arthritis May Be Worse in Poor Countries, but Seem Worse in Rich Ones

Janice Neumann  |  

(Reuters Health)—A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms. The results, tallied from 17 countries, suggest that cultural factors may influence patients’ perception of their illness, and possibly even the results of clinical trials…

Self-Monitoring of RA Treatment May Lead to Fewer Office Visits

Reuters Staff  |  

NEW YORK (Reuters Health)—Self-monitoring of methotrexate therapy may curb healthcare utilization in rheumatoid arthritis (RA) and psoriatic arthritis, according to a new trial. The study indicates “that this novel model of care led to significant reductions in outpatient visits to the (clinical nurse specialist) and a reduction in visits to the GP, while maintaining the…

Growth Hormone Reduces Fractures in Women with Osteoporosis

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…

Use Behavioral ‘Nudging’ to Tackle Gender, Health Challenges

Joseph D'Urso  |  

LONDON (Thomson Reuters Foundation)—Many of the world’s biggest challenges, such as encouraging people to buy life-saving drugs or unpicking deeply rooted sexism, can be tackled by using subtle psychological cues to change the way people behave, according to experts in London. Behavioral economics, also known as “nudging,” is about making people more likely to make…

Novartis Launches First U.S. Biosimilar Drug at 15% Discount

Ben Hirschler & Michael Shields  |  

LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…

Governments Are Not Following Advice on MERS

Tom Miles  |  

GENEVA (Reuters)—Governments are not doing all they should to tackle the deadly Middle East Respiratory Syndrome, a committee of health experts at the World Health Organization said on Thursday. The WHO’s emergency committee, which meets regularly to consider the international response to the disease, said in a statement that its advice had not been completely…

Alcohol Use Complicates Chronic Disease Management in Teens

Will Boggs, MD  |  

NEW YORK (Reuters Health)—High school students with chronic medical conditions who drink alcohol are more likely than their nondrinking peers to forget or skip taking their medications, according to an online survey. “I was surprised to see such a clear association between alcohol use and medication nonadherence—a finding which really brings home the need to…

Can We Get Closer to a Cure for RA?

Marc Feldmann & Ravinder N. Maini  |  

Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs

Reuters Staff  |  

(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…